Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - chloramphenicol -

United States - English - NLM (National Library of Medicine)

havix group inc d-b-a aavis pharmaceuticals - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - malaria hydroxychloroquine sulfate tablets is indicated for the treatment of uncomplicated malaria due to p. falciparum, p. malariae, p. ovale, and p. vivax. hydroxychloroquine sulfate tablets is indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use in malaria - hydroxychloroquine sulfate tablets is not recommended for the treatment of complicated malaria. - hydroxychloroquine sulfate tablets is not effective against chloroquine or hydroxychloroquine-resistant strains of plasmodium species (see clinical pharmacology – microbiology ). hydroxychloroquine sulfate tablets is not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium species has not been identified. - hydroxychloroquine sulfate tablets is not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. - hydroxychloroquine sulfate tab

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - hydroxychloroquine sulfate - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - hydroxychloroquine sulfate - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - hydroxychloroquine sulfate - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - hydroxychloroquine sulfate - oral tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - hydroxychloroquine sulfate - oral tablet - 200mg

United States - English - NLM (National Library of Medicine)

sandoz inc - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate is indicated in adult and pediatric patients for the: limitations of use hydroxychloroquine sulfate is not recommended for: for the most current information about drug resistance, refer to the latest recommendations from the center for disease control and prevention1. hydroxychloroquine sulfate is indicated for the treatment of acute and chronic rheumatoid arthritis in adults. hydroxychloroquine sulfate is indicated for the treatment of systemic lupus erythematosus in adults. hydroxychloroquine sulfate is indicated for the treatment of chronic discoid lupus erythematosus in adults. hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to hydroxychloroquine sulfate during pregnancy. encourage patients to register by contacting 1-877-311-8972. risk summary prolonged clinical experience over decades of use a

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: limitations of use: hydroxychloroquine sulfate tablets are not recommended for: for the most current information about drug resistance, refer to the latest recommendations from the center for disease control and prevention1 . hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. hydroxychloroquine sulfate tablets are indicated for the treatment of systemic lupus erythematosus in adults. hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus in adults. hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to hydroxychloroquine sulfate tablets during pregnancy. encourage patients to register by contacting 1-877-311-8972.

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - hydroxychloroquine sulfate (unii: 8q2869cnvh) (hydroxychloroquine - unii:4qwg6n8qkh) - hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: - treatment of uncomplicated malaria due to plasmodium falciparum, plasmodium malariae, plasmodium vivax,  and plasmodium ovale . - prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. limitations of use: hydroxychloroquine sulfate tablets are not  recommended for: - treatment of complicated malaria. - treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of plasmodium species [see microbiology(12.4)] . - treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the plasmodium  species has not been identified. - prophylaxis of malaria in geographic areas where chloroquine resistance occurs. - prevention of relapses of p. vivax  or p. ovale  because it is not active against the hypnozoite liver stage forms of these parasites. for radical cure of p. vivax  and p. ovale  infections, concomitant therapy with an 8-aminoquinoline drug